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Insights into immune reactions against benign and malignant melanocytes may help the development of more efficient
immunotherapeutic treatments for melanoma. The interplay between an active systemic antitumor immunity and a
responsive local tumor environment is crucial to achieve effective clinical responses. Increasing evidence confirms this
strategy can lead to an adequate and durable immunosurveillance of melanocytes.
The immunosurveillance of benign and
malignant melanocytes is a very relevant
research topic as this may provide new
insights in immunotherapeutic strategies
for melanoma. Different aspects of the
immune response against melanocytes
can be investigated by in vivo models
that represent a depressed (melanoma),
an adequate (halo nevi) and an over-
active (vitiligo) immunosurveillance against
melanocytes.
Regression is microscopically detected
in up to 20–30% of melanoma lesions.
Spontaneous or therapy-induced vitiligo-
like depigmentation has been observed in
2–7% of melanoma patients and has been
linked to a better prognosis.
1 Nevertheless,
the prognosis of advanced stage melanoma
patients remains currently poor. The dif-
ferent immune escape mechanisms used
by tumor cells are becoming more and
more clear and may reveal new targets
for immunotherapy. Numerous tumor
escape mechanisms have been described
including the development of regulatory
T cells, myeloid suppressor cells and the
expression of immune-depressing markers
such as cytotoxic T-lymphocyte antigen
4 (CTLA-4), programmed cell death
1-ligand 1 (PD-L1) and indoleamine 2,3-
dioxygenase (IDO).
2
Despite these immunosuppressing
factors, several remarkable examples of
spontaneous immune responses have
been reported in melanoma patients. We
recently reported a case of a patient with a
history of melanoma who showed regres-
sion of almost all nevi over time.
3 This
regression was only clinically apparent by
follow up pictures as no depigmented
halos around the disappearing nevi were
observed. By demonstrating lesional and
circulating melanocyte-specific cytotoxic
T cells, we confirmed the immune-
mediated elimination of these nevoid
melanocytes, which suggests that this
patient has spontaneously developed
an efficient immunosurveillance against
melanocytes. This raises the question
whether an induction of melanocyte-
specific T cells by vaccination could be a
prevention strategy in patients with very
high risk of melanoma e.g., patients who
carry cyclin-dependent kinase inhibitor
2A (CDKN2A) mutation or patients with
dysplastic nevus syndrome and a family
history of melanoma. Regression of nevi
after vaccination is however not well
documented and one previous study could
not find an increased immune infiltrate
in nevi of glycoprotein 100 (gp100)—and
tyrosinase-peptide vaccinated melanoma
patients.
4 Halo nevi have been proposed
as a sign of immunosurveillance. Nonethe-
less, this phenomenon is mostly observed
in young adolescents, whereas the mean
age of melanoma patients ranges around
45–60 years. Despite some occasional
cases of vaccinated melanoma patients,
clear evidence of regression of nevi in the
context of melanoma is lacking.
5 How-
ever, elimination of normal epidermal
melanocytes leading to vitiligo-like depig-
mentation is a well-known phenomenon
in melanoma. Moreover, melanoma asso-
ciated depigmentation is relatively fre-
quently observed after immunotherapy
and has been linked to a beneficial
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prognosis. Further investigation of this
topic seems warranted.
In another study, we showed that a
subset of patients with multiple halo nevi
can develop limited ectopic depigmented
areas (which are not located in regions
of regressing nevi). As these lesions are
not in accordance with the classic vitiligo
criteria, we proposed an entity of halo
nevi associated leukoderma, which is a
similar phenomenon as the vitiligo-like
depigmentations observed in melanoma
patients. Moreover, halo nevi associated
leukoderma and melanoma associated
depigmentation seem to have some com-
mon clinical characteristics (mainly dis-
crete depigmentations with a limited
progressive behavior) and may be an
example of collateral damage resulting
from melanocyte immunosurveillance.
Previous studies have demonstrated
that the induction of antigen specific T
cells alone is insufficient to induce depig-
mentation. Local increased oxidative stress
(e.g., local trauma), causing enhanced
levels of H2O2, stimulates tyrosinase
activity. As a consequence, increased
amounts of surrogate substrates of tyrosi-
nase are converted to ortho-quinones,
which are highly immunogenic when
bound to tyrosinase (= haptenation) and
induce the development of antigen-
specific CD8 cells (Fig.1).
6 Multiple
regressing nevi and halo nevi/melanoma
associated leukoderma may be due to
a haptenation process linked to the
oxidative stress associated with the halo
phenomenon. An example of a local
haptenation process leading to elimination
of melanocytes at distant sites is observed
with chemical depigmenting agents (e.g.,
monobenzone) in vitiligo. This indicates
the development of a systemic melanocyte-
destructive inflammatory response and
monobenzone has consequently also been
proposed to be effective in melanoma.
7
Evidence that increased stress is crucial
for developing melanocyte destruction
can be found in the koebner phenomenon
in vitiligo. Physical trauma elicits an
immune response and depigmentation at
the injured area. We recently developed an
in vivo koebner induction model in
vitiligo.
8 As in our study all induction
Figure1. Presentation of an efficient immune response (right) enhanced by oxidative stress leading to haptenation. This leads to increased antigen
presentation and ultimately the development of melanocyte-specific CD8 cells occurs which are recruited toward the tumor site. In the model illustrating
immune tolerance of the tumor (left), no active tumor elimination is present and immune-suppressing factors at the primary melanoma and in the tumor
draining lymph node maintain the tumoral immune escape.
AUTHOR'S VIEW
www.landesbioscience.com OncoImmunology 527© 2012 Landes Bioscience.
Do not distribute.
methods were effective, it seems that a
non-specific triggering of the release of
oxidative factors is sufficient to induce
depigmentation in vitiligo patients. Future
research with this model may determine
whether the individual likelihood for
koebner induced reactions resides in the
degree of oxidative stress resulting from
trauma. The koebner phenomenon is an
example demonstrating that both the
systemic immune response as local factors
are necessary for melanocyte elimination.
Whereas vaccination in melanoma is an
attractive method to enhance systemic
immune-specific responses, it is dependent
on the local tumor environment to be
effective. As the tumor develops several
strategies to suppress active inflammation,
the antitumoral lymphocytes do often not
exert their potential activity at the tumor
site limiting the efficacy of vaccination.
Agents inducing a local, innate immune
response can be crucial to overcome this
hurdle. A treatment such as imiquimod—a
topical immunomodulator which activates
Toll-like receptor 7—has been shown to
increase inflammation in melanoma lesions
and may enhance the efficacy of vaccins
by reversing the local tumor suppressive
environment.
9 Anti-PD-L1 and anti-IDO
therapy seem also promising options to
overcome tumoral immune escape.
The development of an efficient
immunosurveillance of melanocytes may
have a preventive effect (as illustrated by
our case of a melanoma patient with
regressing nevi) and is crucial for an early
effective antitumoral immune response.
Both halo associated leukoderma and the
koebner phenomenon in vitiligo suggest
the importance of oxidative stress leading
to a process of haptenation. Currently,
this may be an underappreciated pheno-
menon in the immune-based treatment
of melanoma. As most research has now
focused on developing tumor-antigen
specific T cells (e.g., vaccination) and
activating lymphocytes (e.g., anti-CTLA-
4), more research is needed to efficiently
recruit these cells to an inflammation-
prone tumoral environment.
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